Investigational Drug for Scleroderma-associated PAH

Trial Objective

The purpose of this study is to determine if a new investigational medication, Tecfidera®, helps people with systemic sclerosis-associated pulmonary arterial hypertension (PAH). Tecfidera is currently FDA approved for use in patients with multiple sclerosis.

Investigational Drug for Scleroderma-associated PAH

Enrollment

This trial is active and currently recruiting.

How to Participate

For more information, call 303.270.2348 or complete the form below.

Who Can Participate

Individuals ages 18-80 who have systemic sclerosis-associated pulmonary arterial hypertension and are currently on stable medical therapies for PAH.


Estimated Time Commitment

6 visits over 40 weeks

Two telephone visits at weeks 1 and 4. Approximately 20 hours total.

Trial Location

National Jewish Main Campus, Denver, CO

Compensation

Provided

Trial Sponsors

National Institutes of Health (NIH)

Age

18-80


Gender

Any Gender

Principal Investigators


Request More Information

*
*
*
*